Biomarkers of depression in cancer patients

Cancer

Volumn 107, Issue 11, 2006, Pages 2723-2729

  Jehn, Christian Friedrich ^a   Kuehnhardt, Dagmar ^a   Bartholomae, Andrea ^a   Pfeiffer, Sebastian ^a   Krebs, Michael ^a   Regierer, Anne Constanze ^a   Schmid, Peter ^a   Possinger, Kurt ^a   Flath, Bernd Christian ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Biomarkers; Cancer; Depression; Hypothalamic pituitary adrenal (HPA) axis; Interleukin 6

Indexed keywords

BIOLOGICAL MARKER; HYDROCORTISONE; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; CANCER PATIENT; CIRCADIAN RHYTHM; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

CROSS-SECTIONAL STUDIES; DEPRESSION; FEMALE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INTERLEUKIN-6; MALE; MIDDLE AGED; NEOPLASMS; PITUITARY-ADRENAL SYSTEM; TUMOR MARKERS, BIOLOGICAL;

EID: 33751556477     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22294     Document Type: Article

References (48)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association 1994.
2. Spiegel D, Bloom JR, Kraemer HC, et al. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet. 1989;II:888-891.
3. Deuschle M, Schweiger U, Weber B, et al. Diurnal activity and pulsatiliy of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls. J Clin Endocrinol Metab. 1997;82:234-238.
4. Nemeroff C, Widerlov E, Bissette G. Elevated cerebrospinal fluid concentrations of corticotropin-releasing factor-like immunoreactivity in major depression. Science. 1984;226:1342-1344.
5. Holsboer F, von Bardeleben U, Wiedemann K, Muller OA, Stalla GK. Serial assessment of corticotropin-releasing hormone response after dexamethasone in depression. Implications for pathophysiology of DST nonsuppression. Biol Psychiatry. 1987;22:228-234.
6. Heuser I, Yassouridis A, Holsboer F. The combined dexamethason/CRH test: a refined laboratory test for psychiatric disorder. J Psychiatr Res. 1994;28:341-356.
7. Zobel AW, Yassouridis A, Frieboes RM, Holsboer F. Prediction of medium-term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression. Am J Psychiatry. 1999;156:949-951.
8. Zobel AW, Nickel T, Sonntag A, Uhr M, Holsboer F, Ising M. Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression: a prospective study. J Psychiatr Res. 2001;35:83-94.
9. Young EA, Altemus M, Lopez JF, et al. HPA axis activation in major depression and response to fluoxetine: a pilot study. Psychoneuroendocrinology. 2004;29:1198-1204.
10. Danzer R, Bluthke RM, Kent S, Goddall G. Behavioral effects of cytokines: an insight into mechanisms of sickness behavior. Methods Neurosci. 1993;17:130-144.
11. Sluzewska A, Rybakowski J, Bosamans E, et al. Indicators of immune activation in major depression. Psychiatry Res. 1996;64:161-167.
12. Musselman DL, Miller AH, Porter MR, et al. Higher than normal plasma Interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry. 2001;158:1252-1257.
13. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 1998;128:127-137.
14. Vuoristo MS, Kellokumpu-Lehtinen P, Laine S, et al. The value of serum S-100beta and interleukins as tumour markers in advanced melanoma. Melanoma Res. 2000;10:237-241.
15. Breuninger LM, Dempsey WL, Uhl J, Murasko DM. Hydrocortisone regulation of interleukin-6 protein production by a purified population of human peripheral blood monocytes. Clin Immunol Immunopathol. 1993;69:205-214.
16. Papanicolaou DA, Petrides JS, Tsigos C, et al. Exercise stimulates interleukin-6 secretion: inhibition by glucocorticoids and correlation with catecholamines. Am J Physiol. 1996;271:E601-E605.
17. Wilkinson CW, Peskind ER, Raskind MA. Decreased hypothalamic-pituitary- adrenal axis sensitivity to cortisol feedback inhibition in human aging. Neuroendocrinology. 1997;65:79-90.
18. Smith PC, Hobisch A, Lin DI, Culig Z, Keller ET. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev. 2001;12:33-40.
19. Scambia G, Testa U, Panici PB, et al. Interleukin-6 and serum levels in patients with gynaecological tumors. Int J Cancer. 1994;57:318-323.
20. Berek JS, Chung C, Kaldi K, Watson JM, Knox RM, Martionez-Maza O. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 1991;164:1038-1043.
21. Endicott J. Measurement of depression in patients with cancer. Cancer. 1984;53:2243-2248.
22. Massie MJ. Depression. In: Holland JC, Rowland JH, editors. Handbook of Psychooncology: Psychological Care of the Patient with Cancer. New York: Oxford University Press; 1989:283-290.
23. Derogatis LR, Morrow GR, Fetting J. The prevalence of psychiatric disorders among cancer patients. JAMA. 1983;249:751-757.
24. Bukberg J, Penman D, Holland JC. Depression in hospitalized cancer patients. Psychosom Med. 1977;39:264-276.
25. Massie MJ. Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr. 2004;32:57-71.
26. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Evaluation of Chemotherapeutic Agents. New York: Columbia University Press; 1949:191.
27. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV axis I disorders. Research version, patient ed. New York: Biometrics Research, New York State Psychiatric Institute; 1999.
28. Moorey S, Greer S, Watson M, et al. The factor structure and factor stability of the Hospital Anxiety and Depression Scale in patients with cancer. Br J Psychiatry. 1991;158:255-259.
29. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361-370.
30. Bisson JI, Chubb HL, Bennet S, et al. The prevalence and predictors of psychological distress in patients with early localized prostate cancer. BJU Int. 2002;90:56-61.
31. Lesperance F, Frasure-Smith N. Depression in patients with cardiac disease: a practical review. J Psychosom Res. 2000;48:379-391.
32. Dickens C, McGowan L, Clark-Carter D, Creed F. Depression in rheumatoid arthritis: a systemic review of the literature with meta-analysis. Psychosom Med. 2002;64:52-60.
33. Dentino AN, Pieper CF, Rao MK, et al. Association of interleukin-6 and other biological variables with depression in older people living in the community. J Am Geriatr Soc. 1999;47:6-11.
34. Constanzo ES, Lutgendorf S, Sood A, Anderson B, Sorosky J, Lubaroff D. Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer. 2005;104:305-313.
35. Kagaya A, Kugaya A, Takebayashi M, et al. Plasma concentrations of interleukin-1beta, interleukin-6, soluble interleukin-2 receptor and tumor necrosis factor alpha of depressive patienls in Japan. Neuropsychobiology. 2001;43:59-62.
36. Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab. 1993;77:1690-1694.
37. Besedovsky HO, Del Rey A. Immune-neuro-endocrine interaction: facts and hypotheses. Endocr Rev. 1996;17:64-102.
38. Miller AH, Pariante CM, Pearce BD. Effects of cytokines on glucocorticoid receptor expression and function. Glucocorticoid resistance and relevance to depression. Adv Exp Med Biol. 1999;461:107-116.
39. Maes M, Bosmans E, Dejongh R, Kenis G, Vandoolaeghe E, Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine. 1997;9:853-858.
40. Peteet J, Tay V, Choen G, MacIntyre J. Pain characteristics and treatment in an outpatient cancer population. Cancer. 1986;57:1259-1265.
41. Gregory RJ, Jimerson DC, Walton BE, Daley J, Paulsen RH. Pharmacotherapy of depression in the medically ill: directions for future research. Gen Hosp Psychiatry. 1992;14:36-42.
42. Kathol RG, Mutigi A, Williams J, Clamon G, Noyes R. Diagnosis of major depression in cancer patients according to four sets of criteria. Am J Psychiatry. 1990;147:1021-1024.
43. Cohen-Cole SA, Brown FW, McDaniel JS. Diagnostic assessment of depression in the medically ill. In: Stoudemire A, Fogel B, editors. Psychiatric Care of the Medical Patient. New York: Oxford University Press; 1993:53-70.
44. Harter M, Woll S, Wunsch A, Bengel J, Reuter K. Screening for mental disorders in cancer, cardiovascular and musculoskeletal disease. Soc Psychiatry Psychiatr Epidemiol. 2006;41:56-62.
45. Bjelland I, Dahl A, Hang T, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychiat Res. 2002;52:69-77.
46. Costa E, Mogos I, Toma T. Efficacy and safety of mianserin in the treatment of depression of women with cancer. Acta Psychiatr Scand. 1985;72:85-92.
47. Stoudemire A, Thompson TL. Medication non-compliance: systematic approaches to evaluation and intervention. Gen Hosp Psychiatry. 1983;5:233-239.
48. Koenig HG, Shelp F, Goli V, Cohen HJ, Blazer DG. Survival and healthcare utilization in elderly medical inpatients with major depression. J Am Geriatr Soc. 1989;37:599-606.